Skip to main content

Adial Pharmaceuticals, Inc.

ADIL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001513525

In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 3 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Adial Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
3 filings
1 insider, $106.3K in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$106.3K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Adial Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Adial Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Young Wendy B.Director–Sep 21, 20262
Coastlands Capital LP10% Owner388,308IndirectJul 16, 20263
Davidson MattChief Development Officer1,923IndirectJun 16, 20261
Claiborne Cary JChief Executive Officer40,417Apr 9, 20261
Goodman TonyChief Operating Officer26,523Apr 9, 20261
Anderson J. KermitDirector–Apr 9, 20261
Schuyler KevinDirector9,213Apr 9, 20261
Gilliland Robertson H.Director9,185Apr 9, 20261
Shah VinayChief Financial Officer17,325Apr 9, 20261
Newman James W. Jr.Director34,644IndirectJun 2, 20250
Truluck JosephChief Financial Officer265,139Mar 27, 20240
Johnson Bankole A.Director148,246IndirectJun 2, 20230
Stilley William B. IIIDirector1,261,779May 25, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 16, 2026 (view filing)5:08 PM ETJul 14-162 daysCoastlands Capital LP10% OwnerPPurchase+3.23K$2.69+$8.69K+0.8%388.3K after2 lots
Jul 13, 2026 (view filing)10:30 AM ETJul 9-104 daysCoastlands Capital LP10% OwnerPPurchase+11.8K$2.78+$32.6K+3.1%385.1K after2 lots
Jul 1, 2026 (view filing)10:30 AM ETJun 292 daysCoastlands Capital LP10% OwnerPPurchase+25.0K$2.60+$65.0K+7.2%373.3K after
Jun 16, 2026 (view filing)Jun 124 daysYoung Wendy B.DirectorPPurchase+36.4K$2.75+$100.0K–36.4K afterDerivative
Oct 3, 2023 (view filing)Sep 294 daysSchuyler KevinDirectorPPurchase+700$2.74+$1.92KNew position700 after
Jan 3, 2022 (view filing)Dec 30, 20214 daysNewman James W. Jr.DirectorPPurchase+10.0K$2.66+$26.6K+100.0%20.0K after
Jan 3, 2022 (view filing)Dec 30, 20214 daysNewman James W. Jr.DirectorPPurchase+15.0K$2.71+$40.7K+76.4%34.6K after2 lots
Dec 1, 2021 (view filing)Nov 29-302 daysStilley William B. IIIChief Executive OfficerPPurchase+20.6K$2.67+$55.0K+2.2%937.6K after2 lots
Nov 30, 2021 (view filing)Nov 264 daysNewman James W. Jr.DirectorPPurchase+10.0K$2.85+$28.5K+40.9%34.5K after
Oct 6, 2021 (view filing)Oct 42 daysJohnson Bankole A.Chief Medical OfficerSSale−200.0K––−57.4%148.2K after